{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:25:21Z","timestamp":1792632321220,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1016\/s1470-2045(03)01034-9","type":"journal-article","created":{"date-parts":[[2003,4,23]],"date-time":"2003-04-23T19:53:40Z","timestamp":1051127620000},"page":"224-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":198,"title":["Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy"],"prefix":"10.1016","volume":"4","author":[{"given":"Kellie A","family":"Slaviero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent P","family":"Rivory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(03)01034-9_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00003088-199834040-00005","article-title":"Predicting effective drug concentrations for individual patients: determinants of pharmacodynamic variability","volume":"34","author":"Levy","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/S1470-2045(03)01034-9_bib2","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1200\/JCO.1996.14.9.2590","article-title":"Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative","volume":"14","author":"Gurney","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2125.1995.tb05796.x","article-title":"The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions","volume":"40","author":"Kivisto","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1172\/JCI113933","article-title":"Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P450: studies in rats and patients","volume":"83","author":"Watkins","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/S1470-2045(03)01034-9_bib5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjc.6600448","article-title":"Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients with an acute-phase response","volume":"87","author":"Rivory","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(03)01034-9_bib6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(03)01034-9_bib7","series-title":"Human cytokines: their role in disease and therapy","first-page":"7","article-title":"Role of cytokines in acute-phase response","author":"Richards","year":"1995"},{"key":"10.1016\/S1470-2045(03)01034-9_bib8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/ajcp\/105.5.589","article-title":"Cytokine function: a study in biologic diversity","volume":"105","author":"Cohen","year":"1996","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib9","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/ki.1997.184","article-title":"The importance of context in cytokine action","volume":"51","author":"Sporn","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/S1470-2045(03)01034-9_bib10","first-page":"99","article-title":"Ethanol and LPS modulate NF-kappaB activation, inducible NO synthase and COX-2 gene expression in rat liver cells in vivo","volume":"7","author":"Spitzer","year":"2002","journal-title":"Front Biosci"},{"key":"10.1016\/S1470-2045(03)01034-9_bib11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11912-002-0023-1","article-title":"The role of C-reactive protein as a prognostic indicator in advanced cancer","volume":"4","author":"Mahmoud","year":"2002","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/S1470-2045(03)01034-9_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/10428190009089433","article-title":"Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis","volume":"37","author":"Vener","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/S1470-2045(03)01034-9_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ijc.10143","article-title":"Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status","volume":"98","author":"Mantovani","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/S1470-2045(03)01034-9_bib14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1096\/fasebj.6.2.1537465","article-title":"Characterization of human cytochrome P450 enzymes","volume":"6","author":"Guengerich","year":"1992","journal-title":"FASEB J"},{"key":"10.1016\/S1470-2045(03)01034-9_bib15","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3109\/03602539709002246","article-title":"Regulation of cytochromes P450 during inflammation and infection","volume":"29","author":"Morgan","year":"1997","journal-title":"Drug Metab Rev"},{"key":"10.1016\/S1470-2045(03)01034-9_bib16","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood.V79.5.1255.1255","article-title":"Heme oxygenase is a positive acute-phase reactant in human Hep3B hepatoma cells","volume":"79","author":"Mitani","year":"1992","journal-title":"Blood"},{"key":"10.1016\/S1470-2045(03)01034-9_bib17","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/0006-2952(94)90391-3","article-title":"Suppression of cytochrome P450IA1 by interleukin-6 in human HepG2 hepatoma cells","volume":"47","author":"Fukuda","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib18","doi-asserted-by":"crossref","first-page":"26969","DOI":"10.1074\/jbc.273.41.26969","article-title":"Down-regulation of cytochrome P450 1A1 gene promoter by oxidative stress: critical contribution of nuclear factor 1","volume":"273","author":"Morel","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/S1470-2045(03)01034-9_bib19","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1023\/A:1011915402914","article-title":"The effect of high-dose endotoxin on CYP3A2 expression in the rat","volume":"15","author":"Roe","year":"1998","journal-title":"Pharm Res"},{"key":"10.1016\/S1470-2045(03)01034-9_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/abbi.2000.1772","article-title":"Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site","volume":"377","author":"Iber","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/S1470-2045(03)01034-9_bib21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1006\/bbrc.2000.3219","article-title":"Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes","volume":"274","author":"Pascussi","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/S1470-2045(03)01034-9_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0006-291X(02)00196-1","article-title":"Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response","volume":"293","author":"Beigneux","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/S1470-2045(03)01034-9_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1254\/jjp.18.224","article-title":"Drug metabolism in tumor-bearing rats: activities of NADPH-linked electron transport and drug-metabolizing enzyme systems in liver microsomes of tumor-bearing rats","volume":"18","author":"Kato","year":"1968","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib24","first-page":"325","article-title":"Effect of toxohormone on microsomal cytochromes and hydroxylating systems of rat liver","volume":"65","author":"Takahashi","year":"1969","journal-title":"J Biochem (Tokyo)"},{"key":"10.1016\/S1470-2045(03)01034-9_bib25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1254\/jjp.18.245","article-title":"Drug metabolism in tumor-bearing rats: in vivo metabolisms and effects of drugs in tumor-bearing rats","volume":"18","author":"Kato","year":"1968","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0014-2964(68)90078-9","article-title":"Prolonged effect of pentobarbital in tumor bearing rats","volume":"4","author":"Rosso","year":"1968","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(03)01034-9_bib27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0014-2964(71)90064-8","article-title":"Impairment of drug metabolism in tumor-bearing animals","volume":"7","author":"Rosso","year":"1971","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(03)01034-9_bib28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0022-3565(25)27909-5","article-title":"An investigation of the decrease in the metabolism of hexobarbital, aminopyrine and p-nitrobenzoic acid by liver from rats bearing a pituitary mammotropic tumor","volume":"160","author":"Wilson","year":"1968","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S1470-2045(03)01034-9_bib29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3181\/00379727-128-33034","article-title":"Hepatic drug metabolism after phenobarbital or 3-methylcholanthrene pretreatment of rats bearing a pituitary tumor","volume":"128","author":"Wilson","year":"1968","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/S1470-2045(03)01034-9_bib30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0006-2952(69)90029-X","article-title":"Metabolic fate of zoxazolamine in tumor bearing rats","volume":"18","author":"Franchi","year":"1969","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib31","first-page":"3557","article-title":"Alterations in hepatic and splenic microsomal electron transport system components, drug metabolism, heme oxygenase activity, and cytochrome P-450 turnover in Murphy-Sturm lymphosarcoma-bearing rats","volume":"42","author":"Schacter","year":"1982","journal-title":"Cancer Res"},{"key":"10.1016\/S1470-2045(03)01034-9_bib32","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/0006-2952(82)90378-1","article-title":"Biochemical basis for impaired drug metabolism in tumor-bearing rats: evidence for altered regulation of hepatic microsomal hemeprotein synthesis","volume":"31","author":"Beck","year":"1982","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/15563657108990487","article-title":"Barbiturate metabolism as affected by neoplastic disease","volume":"4","author":"Boulos","year":"1971","journal-title":"Clin Toxicol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib34","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3181\/00379727-139-36361","article-title":"Evidence that inhibition of hepatic drug oxidation by tumors is mediated by a circulating humor","volume":"139","author":"Boulos","year":"1972","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/S1470-2045(03)01034-9_bib35","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/0006-2952(72)90387-5","article-title":"Prolonged metabolism of pentobarbital in isolated perfused liver of tumor bearing rats","volume":"21","author":"Bartosek","year":"1972","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3565(25)31610-1","article-title":"Drug metabolism in rats bearing a pituitary mammotropic tumor","volume":"209","author":"Villeneuve","year":"1979","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S1470-2045(03)01034-9_bib37","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0006-2952(84)90467-2","article-title":"Alterations in hepatic heme and cytochrome P-450 metabolism in Murphy- Sturm lymphosarcoma-bearing rats: implications for drug metabolism","volume":"33","author":"Schacter","year":"1984","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib38","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/clpt.1985.61","article-title":"Effects of influenza virus vaccine on hepatic drug metabolism","volume":"37","author":"Meredith","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/S1470-2045(03)01034-9_bib39","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1172\/JCI117582","article-title":"Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism","volume":"94","author":"Shedlofsky","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/S1470-2045(03)01034-9_bib40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1046\/j.1365-2125.1997.00603.x","article-title":"Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women","volume":"43","author":"Shedlofsky","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib41","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hep.1840170212","article-title":"Interferon suppresses erythromycin metabolism in rats and human subjects","volume":"17","author":"Craig","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/S1470-2045(03)01034-9_bib42","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/00912700022008955","article-title":"Higher incidence of elevated body temperature or increased C-reactive protein level in asthmatic children showing transient reduction of theophylline metabolism","volume":"40","author":"Yamaguchi","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib43","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-2125.2000.00314.x","article-title":"Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis","volume":"50","author":"Mayo","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1054\/jcaf.2002.127773","article-title":"Plasma levels of TNF-alpha and IL6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure","volume":"8","author":"Frye","year":"2002","journal-title":"J Card Fail"},{"key":"10.1016\/S1470-2045(03)01034-9_bib45","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cpt1977225part1545","article-title":"Plasma protein binding of basic drugs: importance of alpha 1-acid glycoprotein for interindividual variation","volume":"22","author":"Piafsky","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/S1470-2045(03)01034-9_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0009-9236(97)90028-X","article-title":"N-acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow?","volume":"62","author":"O'Neil","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/S1470-2045(03)01034-9_bib47","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3109\/08830189809043015","article-title":"Cytokines and chemokines in HIV infection: implications for therapy","volume":"16","author":"Emilie","year":"1998","journal-title":"Int Rev Immunol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib48","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/clpt.1994.82","article-title":"Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics","volume":"55","author":"Chen","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/S1470-2045(03)01034-9_bib49","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2125.1993.tb04222.x","article-title":"Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients","volume":"36","author":"Israel","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-0609.1999.tb01764.x","article-title":"The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma","volume":"63","author":"Hassan","year":"1999","journal-title":"Eur J Haematol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib51","first-page":"2480","article-title":"Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs","volume":"8","author":"Islam","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(03)01034-9_bib52","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1365-2125.2000.00189.x","article-title":"A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer","volume":"49","author":"Williams","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib53","first-page":"3480","article-title":"Optimizing the erythromycin breath test for use in cancer patients","volume":"6","author":"Rivory","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(03)01034-9_bib54","unstructured":"Slaviero KA, Rivory LP, Seale JP, et al. Measures of inflammatory status correlates with hepatic drug metabolism in cancer patients. Proceedings of the International Congress of Toxicology, Brisbane, Australia 2001: PA39"},{"key":"10.1016\/S1470-2045(03)01034-9_bib55","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.bjp.0704067","article-title":"Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat","volume":"133","author":"Kulmatycki","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/icb.1997.17","article-title":"Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2","volume":"75","author":"Tangye","year":"1997","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib57","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2141.1994.tb05017.x","article-title":"Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo","volume":"88","author":"Jewell","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib58","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1073\/pnas.87.8.3137","article-title":"Interleukin 6 regulates metallothionein gene expression and zinc metabolism in hepatocyte monolayer cultures","volume":"87","author":"Schroeder","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/S1470-2045(03)01034-9_bib59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1432-1033.1994.tb19008.x","article-title":"Induction of metallothionein and stomatin by interleukin-6 and glucocorticoids in a human amniotic cell line","volume":"223","author":"Snyers","year":"1994","journal-title":"Eur J Biochem"},{"issue":"suppl 1","key":"10.1016\/S1470-2045(03)01034-9_bib60","first-page":"S2","article-title":"Cytokine-mediated modulation of cisplatin sensitivity in ovarian cancer cells","volume":"97","author":"Eskandari","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib61","first-page":"4633","article-title":"Endogenous interleukin 6 is a resistance factor for cis- diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines","volume":"55","author":"Borsellino","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/S1470-2045(03)01034-9_bib62","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0006-2952(00)00391-9","article-title":"Nuclear factor-kappa B, cancer, and apoptosis","volume":"60","author":"Bours","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1165\/ajrcmb.17.1.f132","article-title":"The role of nuclear factor-kappa B in cytokine gene regulation","volume":"17","author":"Blackwell","year":"1997","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib64","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1067\/msy.2001.116672","article-title":"Nuclear factor-kappa B is upregulated in colorectal cancer","volume":"130","author":"Lind","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/S1470-2045(03)01034-9_bib65","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0003-4975(00)01635-0","article-title":"Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis","volume":"70","author":"Jones","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/S1470-2045(03)01034-9_bib66","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1038\/sj.onc.1204926","article-title":"Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer","volume":"20","author":"Catz","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/S1470-2045(03)01034-9_bib67","first-page":"39","article-title":"Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro","volume":"21","author":"Milligan","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/S1470-2045(03)01034-9_bib68","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/bjc.1992.433","article-title":"Interleukin 2 therapy in cancer: identification of responders","volume":"66","author":"Broom","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(03)01034-9_bib69","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2249.1995.tb05524.x","article-title":"Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer","volume":"99","author":"Simpson","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib70","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1200\/JCO.1996.14.5.1697","article-title":"Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multi-institutional study","volume":"14","author":"Tartour","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(03)01034-9_bib71","first-page":"649","article-title":"Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer","volume":"5","author":"De Vita","year":"1998","journal-title":"Oncol Rep"},{"key":"10.1016\/S1470-2045(03)01034-9_bib72","first-page":"1427","article-title":"Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma","volume":"19","author":"Zhang","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/S1470-2045(03)01034-9_bib73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1525-1438.2000.00003.x","article-title":"Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel","volume":"10","author":"Penson","year":"2000","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/S1470-2045(03)01034-9_bib74","first-page":"3317","article-title":"Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma","volume":"52","author":"Blay","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/S1470-2045(03)01034-9_bib75","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/bjc.1994.175","article-title":"Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients","volume":"69","author":"Tartour","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(03)01034-9_bib76","first-page":"91","article-title":"A prognostic inflammatory and nutritional index scoring critically ill patients","volume":"55","author":"Ingenbleek","year":"1985","journal-title":"Int J Vitam Nutr Res"},{"key":"10.1016\/S1470-2045(03)01034-9_bib77","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1401::AID-CNCR18>3.0.CO;2-3","article-title":"Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study","volume":"79","author":"Tartour","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(03)01034-9_bib78","first-page":"507","article-title":"Predictive value of nutritional and inflammatory status for topotecan toxicity","volume":"39","author":"Goldwasser","year":"1998","journal-title":"Proc Am Assoc Cancer Res"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204503010349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204503010349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T05:48:44Z","timestamp":1761457724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204503010349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["S1470204503010349"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(03)01034-9","relation":{},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2003,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(03)01034-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}